NEJM: Early convalescent plasma treatment reduces hospitalization risk in outpatient COVID-19 patients

In the United States, about 8% of patients with SARS-CoV-2 infection are hospitalized for Covid-19
.

Most current treatments for Covid-19 aim to reduce the risk of disease progression or death in hospitalized patients, and only three monoclonal antibodies are available for outpatient treatment of Covid -19 , but these drugs are expensive and require 5-7 days after infection

Infection with new coronary pneumonia Recently, researchers examined the effect of SARS-CoV-2 convalescent plasma on preventing disease progression in Covid-19 outpatients

Of the 589 patients who received control plasma transfusions, 37 were hospitalized for Covid-19, and of 592 patients who received plasma from recovered Covid-19 patients, 17 were hospitalized for Covid-19 (6.
3% vs 2.
9%, absolute The analytical difference was 3.

Early convalescent plasma reduces risk of hospitalization in mild patients by 54%

The study concluded that for outpatients with Covid-19, especially the unvaccinated population, receiving convalescent plasma treatment early after symptom onset can reduce the risk of hospitalization for Covid-19 disease progression
.

For Covid-19 outpatients, especially the unvaccinated population, receiving convalescent plasma early after symptom onset reduces the risk of hospitalization for Covid-19 disease progression
.

Original source:
Early Outpatient Treatment for Covid-19 with Convalescent Plasma .
Leave a comment here